利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.031 秒)

    Diagnostic assay for Alzheimer's disease: assessment of A.beta. abnormalities
    1.
    发明授权
    Diagnostic assay for Alzheimer's disease: assessment of A.beta. abnormalities 失效
    阿尔茨海默病的诊断测定：Aβ异常的评估

    公开(公告)号：US5972634A

    公开(公告)日：1999-10-26

    申请号：US817423

    申请日：1997-08-04

    申请人： Rudolph E. Tanzi ,  Ashley I. Bush ,  Robert D. Moir

    发明人： Rudolph E. Tanzi ,  Ashley I. Bush ,  Robert D. Moir

    IPC分类号： G01N33/553 ,  G01N33/53

    CPC分类号： G01N33/553 ,  G01N2800/2821 ,  Y10S435/975

    摘要： The disclosed invention relates to assays for detecting and quantifying A.beta. peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A.beta. peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A.beta. peptides from biological fluids are taught.

    摘要翻译： PCT No.PCT / US94 / 11895 Sec。 371日期：1997年8月4日 102（e）日期1997年8月4日PCT 1994年10月19日PCT PCT。 第WO96 / 12544号公报 日期1996年5月2日所公开的发明涉及用重金属阳离子如锌（II）或铜（II）形式的次氮基乙酸涂覆的固体支持物来检测和定量Aβ肽的测定法。 此外，描述了用于进行本发明的测定的诊断试剂盒。 提出了用于检测Aβ肽的测定的改进，其包括形成重金属阳离子/固体支持物复合物。 用于此改进的优选重金属阳离子是次锌乙酸锌（II）或铜（II）形式。 最后，教导了从生物液体中大量纯化Aβ肽的方法和试剂盒。

    Vitro system for determining formation of A&bgr; amyloid
    3.
    发明授权
    Vitro system for determining formation of A&bgr; amyloid 失效
    用于确定Aβ淀粉样蛋白形成的体外系统

    公开(公告)号：US06365414B1

    公开(公告)日：2002-04-02

    申请号：US08294819

    申请日：1994-08-26

    申请人： Rudolph E. Tanzi ,  Ashley I. Bush

    发明人： Rudolph E. Tanzi ,  Ashley I. Bush

    IPC分类号： G01N2175

    CPC分类号： G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  Y10S436/811 ,  Y10T436/25375

    摘要： The invention relates to rapid methods for determining formation of A&bgr; amyloid and screening compounds which inhibit formation of A&bgr; amyloid in vitro, as well as kits for carrying out the present methods. Such an agent used in vivo may prevent, ameliorate or reverse the symptoms of Alzheimer's disease and A&bgr; amyloidotic disorders related to Alzheimer's disease, Down's syndrome, and Guamanian amyotrophic lateral sclerosis/Parkinson's dementia complex. The process described in this invention involves the rapid induction of A&bgr; amyloid by a heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A&bgr;, such as zinc to form amyloid and determination of formation of tinctorial A&bgr; amyloid. Moreover, a method of determining effectiveness of a candidate anti-amyloidotic agent for prevention or treatment of A&bgr; amyloidosis is described which uses cell cultures which express at least a human A&bgr; peptide.

    摘要翻译： 本发明涉及用于确定Aβ淀粉样蛋白的形成和抑制体外抑制Aβ淀粉样蛋白形成的化合物的快速方法，以及用于实施本发明方法的试剂盒。 在体内使用的这种药剂可以预防，改善或逆转与阿尔茨海默病，唐氏综合征和瓜马尼亚肌萎缩性侧索硬化/帕金森氏综合征相关的阿尔茨海默氏病和阿贝氏淀粉样变性疾病的症状。 本发明描述的方法涉及通过能够与至少包含至少6至28个氨基酸的氨基酸（例如锌）的多肽结合的重金属阳离子快速诱导Aβ淀粉样蛋白，以形成淀粉样蛋白并测定着色的淀粉样蛋白的形成。 此外，描述了确定用于预防或治疗Aβ淀粉样变性的候选抗淀粉样变性剂的有效性的方法，其使用至少表达人Aβ肽的细胞培养物。

    Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
    4.
    发明授权
    Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities 失效
    阿尔茨海默病的诊断测定：Abeta异常的评估

    公开(公告)号：US06890727B2

    公开(公告)日：2005-05-10

    申请号：US09425956

    申请日：1999-10-25

    申请人： Rudolph E. Tanzi ,  Ashley I. Bush ,  Robert D. Moir

    发明人： Rudolph E. Tanzi ,  Ashley I. Bush ,  Robert D. Moir

    IPC分类号： G01N33/553 ,  G01N33/53

    CPC分类号： G01N33/553 ,  G01N2800/2821 ,  Y10S435/975

    摘要： The disclosed invention relates to assays for detecting and quantifying Aβ peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of Aβ peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of Aβ peptides from biological fluids are taught.

    摘要翻译： 所公开的发明涉及使用用重金属阳离子如锌（II）或铜（II）形式的次氮基乙酸涂覆的固体支持物来检测和定量Aβ肽的测定法。 此外，描述了用于进行本发明的测定的诊断试剂盒。 提出了用于检测Abeta肽的测定的改进，其包括形成重金属阳离子/固体支持物复合物。 用于此改进的优选重金属阳离子是次锌乙酸锌（II）或铜（II）形式。 最后，教导了从生物液体中大量净化Abeta肽的方法和试剂盒。

    Method for the identification of agents that inhibit or promote cataracts and uses thereof
    7.
    发明授权
    Method for the identification of agents that inhibit or promote cataracts and uses thereof 失效
    用于鉴定抑制或促进白内障及其用途的药剂的方法

    公开(公告)号：US07166472B2

    公开(公告)日：2007-01-23

    申请号：US10983780

    申请日：2004-11-09

    申请人： Lee E. Goldstein ,  Ashley I. Bush

    发明人： Lee E. Goldstein ,  Ashley I. Bush

    IPC分类号： G01N33/00 ,  G01N21/76

    CPC分类号： G01N33/6893 ,  A61K31/47 ,  G01N2500/04 ,  G01N2800/166

    摘要： Described are methods for the identification of agents useful in the treatment or prevention of cataracts. Also described are methods for the identification of agents that may inadvertently promote or accelerate the formation of cataracts, and methods of treating or preventing injuries to or diseases of the ocular lens, retina and/or macula. More specifically, the invention describes methods for the identification of pharmacological agents useful in treating cataracts by inhibiting the cross-linking of eye lens proteins.

    摘要翻译： 描述了用于鉴定可用于治疗或预防白内障的药剂的方法。 还描述了用于鉴定可能不经意地促进或加速白内障形成的药剂的方法，以及治疗或预防眼透镜，视网膜和/或黄斑的损伤或疾病的方法。 更具体地，本发明描述了通过抑制眼晶状体蛋白质的交联来鉴定可用于治疗白内障的药理学试剂的方法。

    Methods for screening drugs to predict tardive dyskinesia
    9.
    发明授权
    Methods for screening drugs to predict tardive dyskinesia 失效
    筛选药物预测迟发性运动障碍的方法

    公开(公告)号：US06316269B1

    公开(公告)日：2001-11-13

    申请号：US09166594

    申请日：1998-10-06

    申请人： Guochuan Tsai ,  Xudong Huang ,  Ashley I. Bush

    发明人： Guochuan Tsai ,  Xudong Huang ,  Ashley I. Bush

    IPC分类号： G01N3300

    CPC分类号： G01N33/84 ,  G01N33/94 ,  G01N2500/00 ,  Y10T436/20 ,  Y10T436/203332 ,  Y10T436/206664

    摘要： The present invention provides screening methods for identifying compounds which induce tardive dyskinesia (TD) when administered to an animal. In particular, the methods involve assaying for intermediates and end products of reactions associated with candidate compound mediated reduction of reducible substrates. Also provided are high-throughput screening methods for determining whether compounds induce TD when administered to an animal. Further, provided are methods for treating psychoses comprising testing antipsychotic drugs to identify those which will not induce TD when administered to an animal and administering one or more such drugs to a patient in need thereof.

    摘要翻译： 本发明提供了当给予动物时鉴定诱导迟发性运动障碍（TD）的化合物的筛选方法。 特别地，该方法包括测定与候选化合物介导的可还原底物的还原相关的反应的中间体和终产物。 还提供了用于确定化合物在给予动物时是否诱导TD的高通量筛选方法。 此外，提供了治疗精神病的方法，包括测试抗精神病药物以鉴定当施用于动物时不会诱导TD并且向有需要的患者施用一种或多种此类药物的那些。